Woodline Partners LP Summit Therapeutics Inc. Transaction History
Woodline Partners LP
- $19.5 Billion
- Q3 2025
A detailed history of Woodline Partners LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Woodline Partners LP holds 214,507 shares of SMMT stock, worth $3.91 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
214,507
Previous 182,012
17.85%
Holding current value
$3.91 Million
Previous $3.87 Million
14.79%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
264Shares Held
94.3MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...